R3 Stem Cell Awards
Over the past 10 years, David Greene, MD, MBA has grown R3 Stem Cell to become a world leader in regenerative therapies. And over the past few years, Awards have started to roll in!
For the first 8 years, R3 was routinely featured in media stories from the likes of Forbes, Entrepreneur, California Business Journal, and affiliates of ABC, CBS, NBC and Fox.
In 2020, R3 Stem Cell initially received an Award for 10 Most Innovative Companies of the Year. This was no surprise, considering the international expansion with such a cost effective offering for patients. This was followed up by an Award for 50 Smartest Companies of the Year. During the interview process for the Award, Dr. Greene was asked, “How did you come up with the idea to expand?”
The answer from Dr. Greene was, “When our company has meetings, I make sure I’m never the smartest person in the room. We have some incredibly smart individuals at R3 whose ideas are simply stellar!”
Another Award received in 2020 included 10 Best Companies of the Year. This Award was given based on the very high patient satisfaction, safety, growth and employee happiness. To culminate the year, R3 Stem Cell received America’s Best Regenerative Therapies Provider from Corporate Vision.
“Considering the amount of regenerative clinics in the US, that Award means a lot to us. It’s great to be recognized as a leader in the field!”
During an interview from one of the Award companies, Dr. Greene was asked a series of questions about R3 Stem Cell. Here is what he said:
Regenerative Medicine, US Technology
Although still considered experimental by the FDA, stem-cell therapy shows impressive outcomes in treating a wide range of conditions, including orthopedic, neurologic, autoimmune, GI, cardiovascular, kidney/liver issues and more. Leading the charge when it comes to advanced stem cell and exosome therapies, R3 Stem Cell operates 70 locations in seven countries, and it is the company’s mission to provide customised, high-quality, affordable treatments to help patients achieve a better quality of life. This has netted its team the well-deserved title of Leading Innovators in Regenerative Cell Therapy 2025 – USA, and we take a deep dive into this innovation below.
For more than a decade, R3 Stem Cell has been providing patients from all over the world with regenerative stem cell and exosome
therapies, treatments designed to harness the natural healing powers of the body and provide patients with hope. This hope often
turns out to be transformative in the lives of individuals dealing with the likes of tissue injuries and chronic pain, and these groups are soon able to do things many of us take for granted – such as hiking, biking, or swimming – without any of their previous discomfort.
The health market is flooded with a number of pain-management therapies, mostly doing a good short term job of relieving symptoms but not actually fixing the root cause of the pain. R3 Stem Cell is much more than simply pain management, and the company has an established track record of long term results for pain relief, which allows patients to avoid surgery as a result of the treatments.
As an example of its distinction in this field, R3 Stem Cell was the first company in the US to achieve approval from an Institutional Review Board for the investigation of regenerative therapies with amniotic and umbilical cord tissue for a number of condition categories. More information about this study is available here, but it essentially corroborates the company’s claim of being an undisputed leader, both in its home of the US and beyond.
Across its unrivalled range of regenerative therapies, R3 Stem Cell’s tissue products come from FDA registered, cGMP-compliant, and
ISO-certified labs. According to R3 CEO David Greene, MD, PhD, MBA, “We never sacrifice quality control testing when producing the
stem cell and exosome products for patients. My family and I receive procedures frequently with our stem cells, and our patients deserve
to be treated like family!”
Behind every procedure in every location – the company deems its 70 sites ‘Centers of Excellence’ – there is a team of experienced, compassionate providers, individuals committed to delivering safe and effective care to their patients at every turn. To date, more than 26,000 of these procedures have been carried out, resulting in an 85% patient satisfaction rate. For something still considered experimental, this is highly impressive.
When it is not setting the gold standard for regenerative therapies through its cutting-edge stem cell procedures, R3 Stem Cell can be found educating consumers on the dangers of cheap stem-cell therapies, which are becoming increasingly popular in this space.
These providers will often refuse to show patients an analysis certificate from the tissue lab – a big red flag. Most of the time, the
tissue is inauthentic and not of the advertised quality. Similarly, some clinics even promote PRP as a stem-cell procedure.
By refusing to sacrifice on the quality it has become famous for, R3 Stem Cell boasts a number of success stories from patients satisfied
with the treatments they received. There are some huge names within this portfolio, including Arnel Pineda, the current lead singer of
the legendary rock band Journey; Ryan Paevey, an actor and model famous for his role in General Hospital; and Otis Wilson, a former
Super Bowl champion.
On the back of this acclaim and these celebrity endorsements, R3 Stem Cell is continuing to move the needle in the field of regenerative therapy, a feat reflected through the title bestowed upon its team in this feature. For more information about any of the therapies discussed above, follow the link below to the company website.
Contact: David Greene, MD, PhD, MBA
Company: R3 Stem Cell
Web Address: https://r3stemcell.com/
Existing pain management therapies have been great for suppressing pain, but R3 Stem Cell is working on a fix. How are you doing this?
Most traditional medical treatments around the world are “band aids.” A classic example of this is when steroid injections are used for arthritis. They may provide relief for a couple weeks, but that’s it. Stem cell and exosome therapies approach tissue damage from arthritis, organ failure, autoimmune disease, neurologic issues, autism, CP and more from a completely opposite approach. This is done through tissue regeneration and repair to actually work on the root of the problem. So, the procedures work tremendously well at this from several different mechanisms:
- Cell-to-cell interactions
- Reducing inflammation
- Modulating the immune system
- Promoting new blood flow
- Reducing cell death
While stem cell therapy is not a cure for any of the conditions we treat, the technology is very safe and improves patient lives by actually repairing damage and restoring missing cells. Results often are long lasting!
How has your journey been so far?
As with any new technology that is disruptive, it has been a bumpy road that has focused on education. Helping consumers and providers understand the biologics, what they can and cannot do and what to expect has helped tremendously. Unfortunately, there are a lot of unscrupulous “players” in the industry who just look to exploit patients with suboptimal treatments while not truly caring about patient outcomes. R3 cares mostly about great outcomes and safety. With 16,000 procedures worldwide over the past decade and no significant adverse events, we are the world’s leader in regenerative therapies. Our patient satisfaction is 85% year over year, and 30% of our patient base is from referrals. The combination of great outcomes, safety, first rate patient experience and very fair pricing has propelled us to where we are now.
Usually, high-profile athletes garner all the attention when it comes to regenerative medicine. Can middle-age and elderly folks benefit from this too?
There are three demographics of individuals who can benefit from regenerative therapies. High-level athletes are definitely one of them, and of course, they generate attention because the public wants to know all about their injuries and treatment. Stem cell therapy is not a performance enhancing drug, so most sports organizations are accepting of the technology.
The second demographic is younger individuals suffering from a chronic disease like diabetes, rheumatoid arthritis, lupus, etc. But by far, the largest demographic using regenerative medicine is older individuals dealing with chronic medical conditions.
When you look at R3 Centers’ worldwide, the average age is 65. We have treated patients as old as 102! So, middle-age and elderly folks make up the vast majority of patients, and the results have been outstanding.
How does R3 Stem Cell stand apart from other regenerative therapy providers?
Most providers offering regenerative therapies simply do not take the time to understand what they are putting into patients and how to best perform the procedures. This is unfortunate, especially, when providers are asking patients to pay a considerable amount.
R3 Stem Cell provides doctors with the most important asset available with new technology – KNOWLEDGE. Our in-person and online training instills providers with accurate information to lean on when it comes to offering regenerative therapies.
In addition, R3 performs extensive marketing for patient acquisition, along with providing the best stem cell and exosome biologics available for amazing pricing. The comprehensive offering helps R3 stand apart from any other regenerative products and services company.
What does the future hold for stem cell treatments?
Existing mesenchymal stem cell therapies are working well for mitigating and improving many diseases. However, the future will allow biological cures for disease as research will eventually permit safe usage of induced pluripotent stem cells (iPSCs) in humans. This technology takes a patient’s own specialized cells and reverts them back to being pluripotent stem cells. It is not ready yet for use in humans due to safety issues, but the technology will eventually be perfected.
